BSX · 10-Q · 2026Q2 · Full report

Market Demand Trends

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 49 · Surprise 32

Boston Scientific reported six-month 2026 organic sales growth of 8.1%, with Cardiovascular growing 9.4% organically and MedSurg growing 5.6%. Cardiovascular demand was supported by coronary therapies and Electrophysiology, while Neuromodulation reported 13.7% organic growth, led by its pain portfolio and deep brain stimulation franchise. Endoscopy delivered 6.9% organic growth, whereas Urology growth was only 0.6% because of weakness in stone procedures in China and disruption in sacral neuromodulation.

Key facts

• Urology reported net sales growth was relatively flat in Q2 and the first six months of 2026, primarily driven by underperformance in the stone franchise due to volume-based-procurement in China and commercial disruption in the sacral neuromodulation franchise. source